Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Porter

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
Blood|January 19, 2012
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J Neufeld, Renzo Galanello, Vip Viprakasit, et al.
American Journal of Hematology|September 1, 2010
Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohortLauren Mednick, Shuli Yu, Felicia Trachtenberg, et al.
Blood|July 21, 2011
Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network reportClaudia R Morris, Hae-Young Kim, Felicia Trachtenberg, et al.
Blood|June 2, 2011
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-upM Domenica Cappellini, Mohamed Bejaoui, Leyla Agaoglu, et al.
Haematologica|January 25, 2012
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia majorDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Haematologica|November 13, 2010
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Blood Cells, Molecules & Diseases|August 17, 2011
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trialsAurelio Maggio, Aldo Filosa, Angela Vitrano, et al.
Blood|December 10, 2009
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemiaDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Blood|December 19, 2014
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia traitEmma Jones, Sant-Rayn Pasricha, Angela Allen, et al.
Circulation|August 3, 2016
Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World: The TIC-TOC Study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR)Amna Abdel-Gadir, Yongkasem Vorasettakarnkij, Hataichanok Ngamkasem, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Blood|January 19, 2012
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J Neufeld, Renzo Galanello, Vip Viprakasit, et al.
American Journal of Hematology|September 1, 2010
Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohortLauren Mednick, Shuli Yu, Felicia Trachtenberg, et al.
Blood|July 21, 2011
Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network reportClaudia R Morris, Hae-Young Kim, Felicia Trachtenberg, et al.
Blood|June 2, 2011
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-upM Domenica Cappellini, Mohamed Bejaoui, Leyla Agaoglu, et al.
Haematologica|January 25, 2012
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia majorDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Haematologica|November 13, 2010
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Blood Cells, Molecules & Diseases|August 17, 2011
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trialsAurelio Maggio, Aldo Filosa, Angela Vitrano, et al.
Blood|December 10, 2009
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemiaDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Blood|December 19, 2014
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia traitEmma Jones, Sant-Rayn Pasricha, Angela Allen, et al.
Circulation|August 3, 2016
Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World: The TIC-TOC Study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR)Amna Abdel-Gadir, Yongkasem Vorasettakarnkij, Hataichanok Ngamkasem, et al.
Pageof 13